Serveur d'exploration Tocilizumab - Exploration (Accueil)

Index « Teeft.i » - entrée « Monoclonal antibodies »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Monoclonal < Monoclonal antibodies < Monoclonal antibody  Facettes :

List of bibliographic references indexed by Monoclonal antibodies

Number of relevant bibliographic references: 34.
[0-20] [0 - 20][0 - 34][20-33][20-40]
Ident.Authors (with country if any)Title
002888 (2013) Velin Z. Spassov [États-Unis] ; Lisa Yan [États-Unis]pH‐selective mutagenesis of protein–protein interfaces: In silico design of therapeutic antibodies with prolonged half‐life
002C26 (2013) Herbert Struemper [États-Unis] ; Cecil Chen [États-Unis] ; Wendy Cai [États-Unis]Population Pharmacokinetics of Belimumab Following Intravenous Administration in Patients With Systemic Lupus Erythematosus
002D40 (2013) Alessandro Allegra [Italie] ; Giuseppa Penna [Italie] ; Andrea Alonci [Italie] ; Sabina Russo [Italie] ; Bruna Greve [Italie] ; Vanessa Innao [Italie] ; Viviana Minardi [Italie] ; Caterina Musolino [Italie]Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma
002D65 (2013) Kristine E. Day [Royaume-Uni] ; Lauren N. Beck [Royaume-Uni] ; Nicholas L. Deep [Royaume-Uni] ; Joy Kovar [États-Unis] ; Kurt R. Zinn [Royaume-Uni] ; Eben L. Rosenthal [Royaume-Uni, États-Unis]Fluorescently labeled therapeutic antibodies for detection of microscopic melanoma
002D93 (2013) M. Schiff [États-Unis] ; M. Dougados [France] ; R. Fleischmann [États-Unis] ; J. Fay [États-Unis] ; M. Maldonado [États-Unis]FRI0257 Abatacept and anti-tnf monoclonal antibodies: efficacy and safety comparisons
002D94 (2013) M. Genovese ; A. Sebba [États-Unis] ; A. Rubbert-Roth [Allemagne] ; J. Scali [Argentine] ; R. Alten [Allemagne] ; J. Kremer [États-Unis] ; L. Pitts [Royaume-Uni] ; E. Vernon [Royaume-Uni] ; R. Van Vollenhoven [Suède]FRI0256 Long-term safety of tocilizumab in patients with rheumatoid arthritis following a mean treatment duration of 3.9 years
002D95 (2013) L. Quartuccio ; M. Fabris ; E. Pontarini ; S. Salvin ; A. Zabotti ; M. Benucci ; M. Manfredi ; D. Biasi ; V. Ravagnani ; F. Atzeni [Italie] ; P. Sarzi Puttini [Italie] ; P. Morassi ; F. Fischetti ; P. Tomietto ; L. Bazzichi [Italie] ; M. Saracco [Italie] ; R. Pellerito [Italie] ; M. Cimmino ; F. Schiavon ; V. Carraro ; A. Semeraro ; R. Caporali ; L. Cavagna ; R. Bortolotti ; G. Paolazzi ; M. Govoni [Italie] ; S. Bombardieri [Italie] ; S. De VitaFRI0255 The 158vv fcgamma receptor 3a genotype is associated with response to rituximab in rheumatoid arthritis: results of an italian multicentre study
003321 (2013) Biljana Smiljanovic [Allemagne] ; Bruno Stuhlmüller [Allemagne] ; Wlodzimierz Maslinski [Pologne] ; Gerd-R Burmester [Allemagne] ; Andreas Radbruch [Allemagne] ; Andreas Grützkau [Allemagne] ; Thomas H Upl [Allemagne]A10.6 Dissecting Disease-Specific Differences in RA and OA by Transcriptome Analyses of Synovial Tissue, Blood and Bone Marrow Monocytes
003322 (2013) Vasco C. Romão [Portugal] ; Maria José Santos [Portugal] ; José Canas Da Silva [Portugal] ; Joaquim Polido Pereira [Portugal] ; José Alberto Pereira Da Silva [Portugal] ; Cátia Duarte [Portugal] ; José Ant Nio Pereira Da Silva [Portugal] ; Cândida Silva [Portugal] ; Ana Assunção Teixeira [Portugal] ; José Antonio Costa [Portugal] ; Domingos Araújo [Portugal] ; Fernando Pimentel Santos [Portugal] ; Jaime Branco [Portugal] ; José Ant Nio Melo Gomes [Portugal] ; Augusto Faustino [Portugal] ; João Eurico Fonseca [Portugal] ; Helena Canhão [Portugal]A10.5 Comparative Effectiveness of Biological Therapies in Rheumatoid Arthritis is Influenced by Response Measures and Disease Activity State
003323 (2013) Till Sörensen [Allemagne] ; Ursula Schulte-Wrede [Allemagne] ; Silvia Pade [Allemagne] ; Heike Hirseland [Allemagne] ; Gerd Burmester [Allemagne] ; Andreas Radbruch [Allemagne] ; Andreas Grützkau [Allemagne] ; Thomas H Upl [Allemagne]A10.4 Automated and Standardised Analysis for High Dimensional Cytometric Data Provides New Options for Complex Cell-Associated Biomarker Screening
003571 (2012) Claire Immediato Daïen [France] ; Yohan Duny [France] ; Thomas Barnetche [France] ; Jean-Pierre Daurès [France] ; Bernard Combe [France] ; Jacques Morel [France]Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis
003618 (2012) P. A. Marichal-Gallardo [Mexique] ; M. M. Álvarez [Mexique]State‐of‐the‐art in downstream processing of monoclonal antibodies: Process trends in design and validation
003621 (2012) Honghui Zhou [États-Unis] ; Yuko Tsukamoto [Japon] ; Hugh M. Davis [États-Unis]Should Clinical Pharmacokinetic Bridging Studies Between Caucasian and Asian Populations Be Required for Approval of Monoclonal Antibodies?
003661 (2012) Melissa M. Coughlin [États-Unis] ; Bellur S. Prabhakar [États-Unis]Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential
003670 (2012) Masahiro Ishikawa [Japon] ; Hiromu Ito [Japon] ; Miki Akiyoshi [Japon] ; Noriaki Kume [Japon] ; Hiroyuki Yoshitomi [Japon] ; Hirokazu Mitsuoka [Japon] ; Shimei Tanida [Japon] ; Koichi Murata [Japon] ; Hideyuki Shibuya [Japon] ; Takashi Kasahara [Japon] ; Akemi Kakino [Japon] ; Yoshiko Fujita [Japon] ; Tatsuya Sawamura [Japon] ; Tadashi Yasuda [Japon] ; Takashi Nakamura [Japon]Lectin‐like oxidized low‐density lipoprotein receptor 1 signal is a potent biomarker and therapeutic target for human rheumatoid arthritis
003678 (2012) Takahiko Sugihara [Japon] ; Naoko Okiyama [Japon] ; Naoto Watanabe [Japon] ; Nobuyuki Miyasaka [Japon] ; Hitoshi Kohsaka [Japon]Interleukin‐1 and tumor necrosis factor α blockade treatment of experimental polymyositis in mice
003689 (2012) Peter Lloyd [Suisse] ; Honghui Zhou [États-Unis] ; Frank-Peter Theil [États-Unis] ; Tarundeep Kakkar [États-Unis] ; Ivan Nestorov [États-Unis] ; Stanley A. Roberts [États-Unis]Highlights From a Recent BIO Survey on Therapeutic Protein‐Drug Interactions
003695 (2012) D A Katzka [États-Unis] ; E V Loftus Jr [États-Unis] ; M. Camilleri [États-Unis]Evolving Molecular Targets in the Treatment of Nonmalignant Gastrointestinal Diseases
003704 (2012) I. Colmegna [Canada] ; B R Ohata [Canada] ; H A Menard [Canada]Current Understanding of Rheumatoid Arthritis Therapy
003716 (2012) Marinos C. Dalakas [États-Unis, Grèce]Biologics and other novel approaches as new therapeutic options in myasthenia gravis: a view to the future
003720 (2012) D. Yehudai [Israël] ; A. Snir [Israël] ; R. Peri [Israël] ; K. Halasz [Israël] ; T. Haj [Israël] ; M. Odeh [Israël] ; A. Kessel [Israël]B Cell‐Activating Factor Enhances Interleukin‐6 and Interleukin‐10 Production by ODN‐Activated Human B Cells

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Teeft.i -k "Monoclonal antibodies" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Teeft.i  \
                -Sk "Monoclonal antibodies" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Teeft.i
   |clé=    Monoclonal antibodies
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021